NextCure/$NXTC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About NextCure
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
- Ticker
- $NXTC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 40
- Headquarters
- Baltimore, United States
- Website
- www.nextcure.com
NextCure Metrics
BasicAdvanced
$27M
-
-$8.27
-
-
Price and volume
Market cap
$27M
52-week high
$15.74
52-week low
$1.55
Average daily volume
66K
Financial strength
Total debt to equity
0.384
Profitability
EBITDA (TTM)
-37.661
Management effectiveness
Valuation
Price to book
2
Price to tangible book (TTM)
2
Growth
Earnings per share change (TTM)
-65.36%
3-year earnings per share growth (CAGR)
-33.64%
NextCure Financial Performance
Revenues and expenses
NextCure Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.